EFFECT OF DRUG THERAPY SUBCLINICAL HYPERTHYROIDIS M ON MARKERS OF CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES

We examined 56 patients (12 men and 44 women) aged 45 to 60 years (mean 51.13 ± 5.32 years) in order to study the dynamics of indicators of endothelial dysfunction in patients with type 2 diabetes with subclinical hyperthyroidism on the background of the natural course and treatment thyrostatics. All patients were divided into two subgroups: the first subgroup received treatment (20 patients) with tyrosol; a second subgroup of dynamic monitoring (36 patients) did not receive treatment during follow-tyrosol. The results indicate an increased risk of cardio-vascular diseases for patients with type 2 diabetes with subclinical hyperthyroidism and require timely active preventive measures.